Filing Flows › Cartesian Therapeutics (RNAC) › R&D spending
Cartesian Therapeutics (RNAC) R&D spending by quarter
Cartesian Therapeutics' R&D spending was $19.5M in Q1 2026 (first quarter 2026), +33% from Q4 2025. Over the last 5 quarters it ranged from $13.8M (Q3 2025) to $19.5M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $19.5M | +33% | +33% |
| Q4 2025 | $14.7M | +6% | — |
| Q3 2025 | $13.8M | -7% | — |
| Q2 2025 | $14.9M | +1% | — |
| Q1 2025 | $14.7M | — | — |
Q1 2026 at a glance
Cartesian Therapeutics, Q1 2026: revenue $78K (-93% year over year), net loss $39.2M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Cartesian Therapeutics' R&D spending?
Cartesian Therapeutics' R&D spending was $19.5M in Q1 2026 (first quarter 2026), +33% from Q4 2025.
How has Cartesian Therapeutics' R&D spending changed?
Over the last 5 quarters it ranged from $13.8M (Q3 2025) to $19.5M (Q1 2026).
Q1 2026 results → · How Cartesian Therapeutics makes money →